The class of drug known as p110δ inhibitors, currently being used to treat leukemia, has the unexpected side-effect of boosting immune responses against many different cancers, according to a study led by pharmaceutical company Genentech in San Francisco
p110δ inhibitors have shown such remarkable efficacy against certain leukemias in recent clinical trials that patients on the placebo were switched to the real drug - but they have not been tested in other types of cancer.
The p110δ enzyme is a member of the PI3-kinase family, and is sometimes called PI3Kδ. p110δ and the other PI3Ks are hot drug targets for the pharmaceutical industry as they are implicated in many cancers and are readily druggable.
A new study in Nature provides the first evidence that such drugs can significantly restrict tumor growth and spread and reduce the chances of relapse for a broad range of cancers. The researchers showed that inhibition of the p110δ enzyme helps to boost the body’s immune system to kill tumor cells.
Lead author Dr Khaled Ali, now based at Amgen, San Francisco, says, “When we first introduced tumors in p110δ-deficient mice, we expected them to grow faster because p110δ is important for the immune system. Instead, some tumors started shrinking. When we investigated this unexpected effect, we found that p110δ is especially important in so-called regulatory T cells which are suppressive immune cells that the tumors engage to protect themselves against immune attack.”
Mouse. Credit: UCL
“Our study shows that p110δ inhibitors have the potential to offer effective immunity to many types of cancer by unleashing the body’s own immune response,” says study co-leader Professor Bart Vanhaesebroeck of the UCL Cancer Institute, who first discovered the p110δ enzyme in 1997. “p110δ is highly expressed and important in white blood cells, called ‘leukocytes’. Given that leukemias are the result of leukocytes becoming cancerous, they are a natural target for p110δ inhibitors. Now, we have shown that blocking p110δ also has the remarkable effect of boosting the body’s immune response against leukemias as well as other cancers.”
The team showed that inhibiting p110δ in mice significantly increased cancer survival rates across a broad range of tumor types, both solid and hematological cancers. For example, mice in which p110δ was blocked survived breast cancer for almost twice as long as mice with active p110δ. Their cancers also spread significantly less, with far fewer and smaller tumors developing. Survival after surgical removal of primary breast cancer tumors was also vastly improved, which has important clinical implications for stopping breast cancer from returning following surgery. The team’s data further show that following p110δ inhibition, the immune system could develop an effective memory response to completely fight off the cancer.
“Our work shows that p110δ inhibitors can shift the balance from the cancer becoming immune to our body’s defences towards the body becoming immune to the cancer, by disabling regulatory T cells,” says study co-leader Dr Klaus Okkenhaug of the Babraham Institute. “This provides a rationale for using these drugs against both solid and blood cancers, possibly alongside cancer vaccines, cell therapies and other treatments that further promote tumour-specific immune responses.”
Professor Nic Jones, Cancer Research UK’s chief scientist and director of the Manchester Cancer Research Centre, said, “Treatments that train the immune system to recognise and kill cancer cells are showing huge promise in several types of cancer. This new finding, although only at an early stage, offers the potential to develop more treatments that can do this in many more cancers, including ones that have real need for more effective treatments such as pancreatic cancer.
“If the findings hold true in cancer patients this could make a big difference to many of them. The good news is that because the drugs used in this study are already being used in the clinic, we could see rapid translation of this research into patient benefit.
Source: University College London
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- Case For Moon: Humanity's Gateway To Solar System Exploration, Open Ended, Planetary Protection At Its Heart
- Mindfulness Is Not A Waste Of Time
- Prohibition 2016: Assessing The UK's Psychoactive Substances Act
- Silencing Cholera's Social Media
- 3 Reasons EPA Sided With Environmentalists Over Science On Methane
- Low Hormone Levels Linked To Obesity In Teens
- Current Atmospheric Models Underestimate The Dirtiness Of Arctic Air
- "The good that Trump already does that is good for science is that he widens the PC-strangled overtone..."
- "Correction, I say that 20 kg of algae solution was needed per person to provide all the oxygen..."
- "Very interesting article Edzard. Not that I disagree with you and those who commented, I would..."
- "Great article about a great study. What is known of African American history jibes with this..."
- "Sweet simple and to the point. The anti sexual harassment training could begin and end right..."
- Our Audience Is Up 700% – And Anti-Science Groups Are Going Nuts
- Tiny Vampires of the Ancient Seas
- Incentivizing Antibiotic Research
- Party Drug for Post-Surgical Pain Prevention
- Hey De Blasio-Get Off Your Sodium Podium!
- The Name Game: How Unethical Environmental Groups and Toxic Fanatics Scare You With Words
- Wind turbines on Galapagos replace millions of liters of diesel since 2007, meet 30 percent of energy needs
- Study shows patients require less painkilling medication after breast-cancer surgery if they have opiate-free anesthesia
- Quiet please in the intensive care unit!
- Premature babies may grow up to have weaker bones
- 90-90-90 HIV initiative would yield 'extraordinary returns' in South Africa